Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Omeros Corporation (OMER)
:OMER
Holding OMER?
Track your performance easily
OMER Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.61 - $13.60
Previous CloseN/A
Volume193.12K
Average Volume (3M)974.46K
Market Cap
$531.98M
Enterprise Value$540.34M
Total Cash (Recent Filing)$45.33M
Total Debt (Recent Filing)$79.51M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Feb 26, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding57,949,760
10 Day Avg. Volume678,270
30 Day Avg. Volume974,457
Standard Deviation0.35
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)341.11
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue480.73
Enterprise Value/Gross Profit360.23
Enterprise Value/Ebitda-3.40
Forecast
1Y Price Target
$22.50Price Target Upside145.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Omeros News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPlans to advance OMS906 to phase 3 development in both PNH and C3G.
Drug DevelopmentOMER believes there is now a path to resubmitting the narsoplimab BLA.
Regulatory FilingsOMER plans to proceed with a BLA resubmission and an EMA filing based on positive statistical analysis results.
Bears Say
Capital RequirementsThe company will need to raise significant additional capital to move its clinical programs forward.
Financial HealthConcerns are noted due to OMER ending with cash of approximately $123 million, debt of around $164 million, and a 'going concern' warning in its financial filing.
Regulatory ApprovalSkepticism remains over FDA approval for narsoplimab due to the lack of new clinical data and the lengthy regulatory process.
---
Ownership Overview
9.70%
Insiders
8.65% Mutual Funds
0.05% Other Institutional Investors
71.28% Public Companies and Individual Investors
OMER FAQ
What was Omeros Corporation’s price range in the past 12 months?
Omeros Corporation lowest stock price was $2.61 and its highest was $13.60 in the past 12 months.
What is Omeros Corporation’s market cap?
Omeros Corporation’s market cap is $531.98M.
When is Omeros Corporation’s upcoming earnings report date?
Omeros Corporation’s upcoming earnings report date is Feb 26, 2025 which is in 39 days.
How were Omeros Corporation’s earnings last quarter?
Omeros Corporation released its earnings results on Nov 13, 2024. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.705 by $0.145.
Is Omeros Corporation overvalued?
According to Wall Street analysts Omeros Corporation’s price is currently Undervalued.
Does Omeros Corporation pay dividends?
Omeros Corporation does not currently pay dividends.
What is Omeros Corporation’s EPS estimate?
Omeros Corporation’s EPS estimate is -0.69.
How many shares outstanding does Omeros Corporation have?
Omeros Corporation has 57,949,760 shares outstanding.
What happened to Omeros Corporation’s price movement after its last earnings report?
Omeros Corporation reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.705. Following the earnings report the stock price went up 65.871%.
Which hedge fund is a major shareholder of Omeros Corporation?
Among the largest hedge funds holding Omeros Corporation’s share is Sheaff Brock Investment Advisors LLC. It holds Omeros Corporation’s shares valued at 0.
---
Omeros Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.50 (145.10% Upside)
$22.50 (145.10% Upside)
Blogger Sentiment
Bullish
OMER Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 60.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.79%
12-Months-Change
Fundamentals
Return on Equity
87.26%
Trailing 12-Months
Asset Growth
-36.45%
Trailing 12-Months
Company Description
Omeros Corporation
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
---
OMER Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development programs, cost reductions, and regulatory advancements, particularly for narsoplimab and zaltenibart. However, financial challenges remain with decreased cash reserves and declining OMIDRIA sales. Despite these challenges, the sentiment leans positive due to strategic advancements and potential new revenue streams.Read More>---
OMER Stock 12 Month Forecast
Average Price Target
$22.50
▲(145.10% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Corcept Therapeutics
―
RedHill Biopharma
―
Cassava Sciences
―
Rigel
―
Amicus
―
Best Analysts Covering OMER
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+73.84%
reiterated a buy rating 9 months ago
Copying Stephen Brozak's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +73.84% per trade.
---